An interventional study of Nasal Spray in Healthy Adults, sponsored by Akita Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Akita Biosciences, Inc. · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 133 studies in Patient Acceptance of Health Care with a site in United States — 23 open to participants now, 35 under way, 1 of them phase 3. Patient Acceptance of Health Care · United States.
Among the 133 studies in Patient Acceptance of Health Care with a site in United States, this one is the 65th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2025, is one of 99 with no phase, and was the 133rd registered.
308 studies on the registry are indexed under Patient Acceptance of Health Care; 53 are open to participants now.
Browse Patient Acceptance of Health Care studies →23 of the 133 studies in Patient Acceptance of Health Care with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18–99
Andrea Wallace · Sites in United States
Ages 18+ · Healthy volunteers
North Carolina State University · Sites in United States
Ages 8–64 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Patient Acceptance of Health Care studies recruiting now, 22 (65%) set no upper age limit and 9 (26%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
133 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 5 · Phase 4 2
First in 1998; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 127 is below the median of 201 across 217 interventional studies indexed under Patient Acceptance of Health Care.
Median enrollment 262 across the 108 interventional studies, 646 across the 24 observational. Of the 90 that completed or were terminated, 34 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 133 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Akita Biosciences, Inc. as lead sponsor.
Akita Biosciences, Inc. has 1 study filed under Patient Acceptance of Health Care — fewer than ten, so there is no comparison to draw.
13 of the studies in Patient Acceptance of Health Care with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217145Phase 3University of UtahPREVENT HPV -Related Cancers Trial | 2026-11 |
| NCT05558332University of California, IrvineYouth Nominated Support Team | 2026-11 |
| NCT05605054Victoria D. OjedaUCSD RELINK: Connecting Adults To Supportive Services | 2026-12-31 |
| NCT06019377Portland State UniversityIntervention to Enhance Coping and Help-seeking Among Youth in Foster Care | 2026-12-31 |
| NCT07542769Northwestern UniversityChoice and Autonomy in Learning Mindfulness for Pediatric Residents | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 133 studies in Patient Acceptance of Health Care with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looked at whether frontline healthcare workers could use a drug-free nasal spray twice a day for 8 weeks, whether it was safe, and whether they found it acceptable.
The spray used in the study (Profi Nasal Spray, Akita Biosciences) was a cosmetic nasal hygiene product made from ingredients already used in nasal and topical products.
Healthcare workers at a public hospital in New York City were randomly assigned to use the spray twice a day for 8 weeks or to receive no spray. The study asked:
Every 3 days, participants answered a short online questionnaire about spray use, side effects, respiratory symptoms, and contact with patients who had COVID-19, influenza, or RSV. Spray use was checked by weighing the bottles at weeks 4 and 8.
To better understand acceptability, about 20 spray users also took part in one-on-one interviews about what it was like to use the spray, including ease of use, fitting it into a daily routine, and anything that made it harder to use.
This was a single-center, open-label, randomized, mixed-methods pilot study of frontline healthcare workers at a public hospital in New York City, conducted during a period of high community activity of influenza, RSV, and COVID-19. Participants were randomized 1:1 to use Profi Nasal Spray twice daily for 8 weeks or to receive no spray. Research staff demonstrated how to use the spray.
Intervention participants received one bottle (about 4 weeks of supply) at enrollment and a second bottle at an in-person visit at week 4. Remaining spray was weighed at weeks 4 and 8 to measure adherence. All participants were reminded about hand hygiene and asked to follow hospital guidance on masks and personal protective equipment.
Every 3 days, all participants completed a short online questionnaire covering spray use, ease of use, scent, stinging or burning and other side effects, contact with patients with confirmed COVID-19, influenza, or RSV, and fever or respiratory symptoms in the past 24 hours. Participants who reported a side effect, an exposure, or new symptoms completed a detailed daily symptom questionnaire until symptoms resolved, and study staff contacted them daily. Participants with symptoms of a respiratory infection were encouraged to be tested for COVID-19, influenza, and RSV at the hospital.
Adverse events were reviewed by a data monitoring team. If spray use stopped for more than 72 hours, participants were followed for adverse events 30 days after the last dose. Respiratory symptoms were monitored in both groups as an additional safety measure.
A subset of intervention participants, selected to represent a range of adherence, side effects, and symptom experiences, completed semi-structured one-on-one interviews about ease of use, adherence, acceptability, and barriers to use. Interviews were audio-recorded, transcribed, and independently coded by two trained researchers using thematic analysis. Coders resolved differences by discussion and consensus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants used the nasal spray, one spray in each nostril twice daily, for 8 weeks. Participants received one bottle (about 4 weeks of supply) at enrollment and a second bottle at week 4. Remaining spray was weighed at weeks 4 and 8 to measure adherence.
Other: Nasal Spray
Participants did not receive a nasal spray. They completed the same questionnaires and study visits as the spray group.
Profi Nasal Spray (Akita Biosciences) is a drug-free nasal spray that forms a thin coating in the nose to help trap and clear airborne particles. It is made from ingredients already used in commercially available nasal and topical products.
Also known as: Profi Nasal Spray, PCANS (Pathogen Capture and Neutralizing Spray)
Feasibility of using the nasal spray
Number of eligible healthcare workers who consented and enrolled in the study and continued to use the nasal spray.
Time frame: 8 weeks
Safety: Number of Participants With Adverse Events
Adverse events in the intervention and control groups, including new nasal discomfort or irritation, stinging or burning, changes in smell or taste, nosebleeds, and respiratory events, with duration and severity.
Time frame: 12 weeks
Acceptability: Adherence to Daily Use and Study Dropout
Adherence: proportion of intervention participants with less than 20% of the expected amount of spray remaining in the bottle (by weight), indicating use of more than 80% of expected doses. Dropout: proportion of participants in each group who withdrew or were lost to follow-up.
Time frame: Week 4 and Week 8
Plan to share: No — There is no plan to make individual participant data publicly available. De-identified data may be shared by the study investigators upon reasonable request.
Ran from Feb 2025 to primary completion in May 2025, 3 months.
Of 154 interventional studies with no phase under Patient Acceptance of Health Care, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Patient Acceptance of Health Care →